Skip to main content
SpringerLink
Log in

Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria

  • Chapter
The Kidney and Hypertension in Diabetes Mellitus

  • 242 Accesses

Abstract

The deleterious effects of systemic blood pressure on glomerular structure were reported more than twenty years ago in a patient with NIDDM and unilateral renal artery stenosis, in which characteristic nodular diabetic glomerulosclerosis was present in the non-ischaemic kidney only [1]. To date the impact of antihypertensive therapy on renal injury in NIDDM has received less attention than in IDDM. This is despite the cumulative incidence of persistent proteinuria and microalbuminuria in NIDDM subjects being comparable in frequency to IDDM subjects of similar duration [2, 3]. The clinical relevance of these figures is reflected by statistics which now show that over 50% of patients entering renal replacement programs have NIDDM [4–7]. Furthermore, in NIDDM the relationship between nephropathy and hypertension is more complex than in IDDM, since hypertension is not necessarily linked to the presence of renal disease, and often precedes the diagnosis of diabetes.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Berkman J, Rifkin H. Unilateral nodular diabetic glomerulosclerosis (Kimmelstiel-Wilson). Report of a case. Metabolism Clin Exp 1973; 22: 715–722.

    Article  CAS  Google Scholar 

  2. Nelson RG, Knowler WC, McCance DR, Sievers ML, Pettitt DJ, Charles MA, Hanson RL, Liu QZ, Bennett PH. Determinants of end-stage renal disease in Pima Indians with type 2 (non-insulin-dependent) diabetes mellitus and proteinuria. Diabetologia 1993; 36: 1087–1093.

    Article  PubMed  CAS  Google Scholar 

  3. Ritz E, Stefanski A. Diabetic nephropathy in type II diabetes. Am J Kidney Dis 1996; 27: 167–194.

    Article  PubMed  CAS  Google Scholar 

  4. Grenfell A, Bewick M, Snowden S, Watkins PJ, Parsons V. Renal replacement for diabetic patients: experience at King’s College Hospital 1980–1989. Q J Med 1992; 85: 861–874.

    PubMed  CAS  Google Scholar 

  5. Excerpts from the United States Renal Data System. 1998 Annual Data Report. Chapter II Incidence and prevalence of ESRD. Am J Kidney Dis 1998; 32(Suppl 1): S39–S49.

    Google Scholar 

  6. Pugh JA, Medina RA, Cornell JC, Basu S. NIDDM is the major cause of diabetic end-stage renal disease. More evidence from a tri-ethnic community. Diabetes 1995; 44: 1375–1380.

    CAS  Google Scholar 

  7. Cowie CC. Diabetic renal disease: racial and ethnic differences from an epidemiologic perspective. Transplant Proc 1993; 25: 2426–2430.

    PubMed  CAS  Google Scholar 

  8. Stornello M, Valvo E, Vasques E, Leone S, Scapellato L. Systemic and renal effects of chronic angiotensin converting enzyme inhibition with captopril in hypertensive diabetic patients. J Hypertension 1989; 7(suppl 7): S65–S67.

    CAS  Google Scholar 

  9. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S. Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney International 1996; 50: 1641–1650.

    Article  PubMed  CAS  Google Scholar 

  10. Bakris GL, Mangrum A, Copley JB, Vicknair N, Sadler R. Effect of calcium channel or beta-blockade on the progression of diabetic nephropathy in African Americans. Hypertension 1997; 29: 744–750.

    Article  PubMed  CAS  Google Scholar 

  11. Bakris GL. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med 1990; 112: 707–708.

    Article  PubMed  CAS  Google Scholar 

  12. Valvo EV, Bedogna V, Casagrande P, Antiga L, Zamboni M, Bommartini F, Oldrizzi L, Rugiu C, Maschio G. Captopril in patients with type II diabetes and renal insufficiency: systemic and renal hemodynamic alterations. Am J Med 1988; 85: 344–348.

    Article  PubMed  CAS  Google Scholar 

  13. Nielsen FS, Rossing P, Gall MA, Skott P, Smidt UM, Parving HH. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy. Diabetes 1994; 43: 1108–1113.

    Article  PubMed  CAS  Google Scholar 

  14. Chan JCN, Ko GTC, Leung DHY, Cheung RCK, Cheung MYF, So WY, Swaminathan R, Nicholls MG, Critchley J, Cockram CS. Long-term effects of angiotensin-converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int, 2000; 57: 590–600.

    Article  PubMed  CAS  Google Scholar 

  15. Fogari R, Zoppi A, Corradi L, Mugellini A, Lazzari P, Preti P, Lusardi P. Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function. J Hum Hypertens 1999; 13: 47–53.

    Article  PubMed  CAS  Google Scholar 

  16. Ferder L, Daccordi H, Martello M, Panzalis M, Inserra F. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19:II237–242.

    Article  PubMed  CAS  Google Scholar 

  17. Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection. Kidney Inter 1992; 41: 912–919.

    Article  CAS  Google Scholar 

  18. Liou HH, Huang TP, Campese VM. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron 1995; 69: 41–48.

    Article  PubMed  CAS  Google Scholar 

  19. Slataper R, Vicknair N, Sadler R, Bakris GL. Comparative effects of different antihypertensive treatments on progression of diabetic renal disease. Arch Intern Med 1993; 153: 973–980.

    Article  PubMed  CAS  Google Scholar 

  20. Romero R, Salinas I, Lucas A, Teixido J, Audi L, Sanmarti A. Comparative effects of captopril versus nifedipine on proteinuria and renal function of type 2 diabetic patients. Diabetes Res Clin Pract 1992; 17: 191–198.

    Article  PubMed  CAS  Google Scholar 

  21. Guasch A, Parham M, Zayas CF, Campbell O, Nzerue C, Macon E. Contrasting effects of calcium channel blockade versus converting enzyme inhibition on proteinuria in african americans with non-insulin-dependent diabetes mellitus and nephropathy. Journal of the American Society of Nephrology 1997; 8: 793–798.

    PubMed  CAS  Google Scholar 

  22. Bakris GL, Weir MR, Dequattro V, McMahon FG. Effects of an ACE inhibitor calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney International 1998; 54: 1283–1289.

    Article  PubMed  CAS  Google Scholar 

  23. Pohl M, Cooper M, Ulrey J, Pauls J, Rohde R. Safety and efficacy of irbesartan in hypertensive patients with type II diabetes and proteinuria. Am J Hypertens 1997; 10: 105A.

    Article  Google Scholar 

  24. Demarie BK, Bakris GL. Effects of different calcium antagonists on proteinuria assocaited with diabetes mellitus. Ann Intern Med 1990; 113: 987–988.

    Article  PubMed  CAS  Google Scholar 

  25. Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron 1998; 80: 175–182.

    Article  PubMed  CAS  Google Scholar 

  26. Gambardella S, Frontoni S, Lala A, Felici MG, Spallone V, Scoppola A, Jacoangeli F, Menzinger G. Regression of microalbuminuria in type II diabetic, hypertensive patients after long-term indapamide treatment. Am Heart J 1991; 122: 1232–1238.

    Article  PubMed  CAS  Google Scholar 

  27. Lacourciere Y, Nadeau A, Poirier L, Tancrede G. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993; 21: 786–794.

    Article  CAS  Google Scholar 

  28. Melbourne Diabetic Nephropathy Study Group. Comparison between perindopril and nifedipine in hypertensive and normotensive diabetic patients with microalbuminuria. Br Med J 1991; 302: 210–216.

    Article  Google Scholar 

  29. Sano T, Kawamura T, Matsumae H, Sasaki H, Nakayama M, Hara T, Matsuo S, Hotta N, Sakamoto N. Effects of long-term enalapril treatment on persistent micro-albuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994; 17: 420–424.

    Article  PubMed  CAS  Google Scholar 

  30. Ruggenenti P, Mosconi L, Bianchi L, Cortesi L, Campana M, Pagani G, Mecca G, Remuzzi G. Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. American Journal of Kidney Diseases 1994; 24: 753–761.

    PubMed  CAS  Google Scholar 

  31. Trevisan R, Tiengo A. Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group. Am J Hypertens 1995; 8: 876–883.

    CAS  Google Scholar 

  32. Velussi M, Brocco E, Frogato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cernigoi AM, Fioretto P, Nosadini R. Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 1996; 45: 216–222.

    Article  PubMed  CAS  Google Scholar 

  33. Agardh CD, Garcia Puig J, Charbonnel B, Angelkort B, Barnett AH. Greater reduction of urinary albumin excretion in hypertensive type II diabetic patients with incipient nephropathy by lisinopril than by nifedipine. J Hum Hypertens 1996; 10: 185–192.

    PubMed  CAS  Google Scholar 

  34. Schnack C, Hoffmann W, Hopmeier P, Schernthaner G. Renal and metabolic effects of 1-year treatment with ramipril or atenolol in niddm patients with microalbuminuria. Diabetologia 1996; 39: 1611–1616.

    Article  PubMed  CAS  Google Scholar 

  35. Fogari R, Zoppi A, Malamani GD, Lusardi P, Destro M, Corradi L. Effects of amlodipine vs enalapril on microalbuminuria in hypertensive patients with type II diabetes. Clinical Drug Investigation 1997; 13: 42–49.

    Article  CAS  Google Scholar 

  36. Romero R, Salinas I, Lucas A, Abad E, Reverter JL, Johnston S, Sanmarti A. Renal function changes in microalbuminuric normotensive type II diabetic patients treated with angiotensin-converting enzyme inhibitors. Diabetes Care 1993; 16: 597–600.

    Article  PubMed  CAS  Google Scholar 

  37. Jerums G, Allen TJ, Tsalamandris C, Cooper ME, Melbourne Diabetic Nephropathy Study Group. Angiotensin Converting Enzyme inhibition and Calcium Channel Blockade in incipient diabetic nephropathy. Kidney Int 1992; 41: 904–911.

    Article  PubMed  CAS  Google Scholar 

  38. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–581.

    Article  PubMed  CAS  Google Scholar 

  39. Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997; 20: 1576–1581.

    Article  PubMed  CAS  Google Scholar 

  40. Cooper ME, Doyle AE. The management of diabetic proteinuria. Which antihypertensive agent? Drugs Aging 1992; 2: 301–309.

    Article  CAS  Google Scholar 

  41. Ravid M, Lang R, Rachmani R, Lishner M. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus. A 7-year follow-up study. Arch Intern Med 1996; 156: 286–289.

    Article  CAS  Google Scholar 

  42. Melbourne Diabetic Nephropathy Study Group, Cooper ME, Allen T, Jerums G, DeLuise M, Alford F, Doyle AE. Effects of different antihypertensive agents on normotensive microalbuminuric type I and type II diabetic patients. Proc XIIth International Congress of Nephrology 1993; Jerusalem

    Google Scholar 

  43. Ravid M, Brosh D, Levi Z, Bardayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus — a randomized, controlled trial. Annals of Internal Medicine 1998; 128: 982–988.

    Article  PubMed  CAS  Google Scholar 

  44. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet 1995; 346: 1403–1407.

    Article  PubMed  CAS  Google Scholar 

  45. Ichikawa I, Madias NE, Harrington JT, King AS, Singh A, Levey AS. Will angiotensin II receptor antagonists be renoprotective in humans? Kidney International 1996; 50: 684–692.

    Article  PubMed  CAS  Google Scholar 

  46. Chan JCN, Critchley J, Tomlinson B, Chan TYK, Cockram CS. Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. American Journal of Nephrology 1997; 17: 72–80.

    Article  PubMed  CAS  Google Scholar 

  47. Os I. Losartan vs. amlodipine in hypertensive patients with NIDDM. Proc 15th International Congress of Nephrology Symposium ‘Emerging therapeutic intervention with AII antagonism in diabetic nephropathy’; 1997.

    Google Scholar 

  48. Lewis EJ, Hunsicker LG, Bain RP, Ronde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.

    Article  PubMed  CAS  Google Scholar 

  49. Rodby RA. Antihypertensive treatment in nephropathy of type II diabetes: role of the pharmacological blockade of the renin-angiotensin system. Nephrol Dial Transplant 1997; 12: 1095–1096.

    Article  PubMed  CAS  Google Scholar 

  50. Brenner B, Shahinfar S, for the RENAAL Investigators. Reduction of endpoints in NIDDM with the angiotensin II antagonist losartan. Proc XVth International Congress of Nephrology 1999;: 163 (abstract 648).

    Google Scholar 

  51. Brown SA, Walton CL, Crawford P, Bakris GL. Long-term effects of antihypertensive regimens on renal hemodynamics and proteinuria. Kidney Int 1993; 43: 1210–1218.

    Article  PubMed  CAS  Google Scholar 

  52. Fioretto P, Frigato F, Velussi M, Riva F, Muollo B, Carraro A, Brocco E, Cipollina MR, Abaterusso C, Trevisan M, Crepaldi G, Nosadini R. Effects of angiotensin converting enzyme inhibitors and calcium antagonists on atrial natriuretic peptide release and action and on albumin excretion rate in hypertensive insulin-dependent diabetic patients. Am J Hypertens 1992; 5: 837–846.

    PubMed  CAS  Google Scholar 

  53. Bakris G, Weir M, De Quattro V, Rosendorff C, McMahon G. Renal effects of a long acting ACE inhibitor, trandolapril (T) or nondihydropyridine calcium blocker, verapamil (V) or in a fixed dose combination in diabetic nephropathy: A randomized double blind placebo controlled multicenter study. Nephrology 1997; 3 (Suppl 1): S271.

    Google Scholar 

  54. Fogari R, Zoppi A, Mugellini A, Lusardi P, Destro M, Corradi L. Effect of benazepril plus amlodipine vs benazepril alone on urinary albumin excretion in hypertensive patients with type ii diabetes and microalbuminuria. Clinical Drug Investigation 1997; 13: 50–55.

    Article  CAS  Google Scholar 

  55. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–2445.

    Article  Google Scholar 

  56. Guidelines Subcommittee. 1999 World Health Organization — International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151–183.

    Google Scholar 

  57. Mogensen CE, Cooper ME. Unpublished data, 1999.

    Google Scholar 

  58. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984; 310: 356–360.

    Article  PubMed  CAS  Google Scholar 

  59. Garber AJ, Vinik AI, Crespin SR. Detection and management of lipid disorders in diabetic patients. A commentary for clinicians. Diabetes Care 1992; 15: 1068–1074.

    CAS  Google Scholar 

  60. Lind L, Pollare T, Berne C, Lithell H. Long-term metabolic effects of antihypertensive drugs. Am Heart J 1994; 128: 1177–1183.

    Article  PubMed  CAS  Google Scholar 

  61. Harper R, Ennis CN, Heaney AP, Sheridan B, Gormley M, Atkinson AB, Johnston GD, Bell PM. A comparison of the effects of low-and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995; 38: 853–859.

    Article  PubMed  CAS  Google Scholar 

  62. Giordano M, Matsuda M, Sanders L, Canessa ML, DeFronzo RA. Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and alpha-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension. Diabetes 1995; 44: 665–671.

    Article  PubMed  CAS  Google Scholar 

  63. Stein P, Black H. Drug treatment of hypertension in patients with diabetes mellitus. Diabetes Care 1991; 14: 425–448.

    Article  PubMed  CAS  Google Scholar 

  64. Laakso M, Karjalainen L, Lempiainenkuosa P. Effects of losartan on insulin sensitivity in hypertensive subjects. Hypertension 1996; 28: 392–396.

    Article  PubMed  CAS  Google Scholar 

  65. Moan A, Hoieggen A, Nordby G, Eide IK, Kjeldsen SE. Effects of losartan on insulin sensitivity in severe hypertension — connections through sympathetic nervous system activity. Journal of Human Hypertension 1995; 9: 50.

    Google Scholar 

  66. Mathiesen ER, Hommel E, Giese J, Parving H-H. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BrMedJ 1991; 303: 81–87.

    CAS  Google Scholar 

  67. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993; 118: 129–138.

    Article  PubMed  CAS  Google Scholar 

  68. Bohlen L, de Courten M, Weidmann P. Comparative study of the effect of ACE-inhibitors and other antihypertensive agents on proteinuria in diabetic patients. Am J Hypertens 1994; 7: 84s–92s.

    PubMed  CAS  Google Scholar 

  69. Weidmann P, Schneider M, Bohlen L. Therapeutic efficacy of different antihypertensive drugs in human diabetic nephropathy: an updated meta-analysis. Nephrol Dial Transpl 1995; 10(suppl): 39–45.

    Google Scholar 

  70. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 1998; 338: 645–652.

    Article  PubMed  CAS  Google Scholar 

  71. Tatti P, Pahor M, Byington RP, DiMauro P, Guarisco R, Strollo G, Strollo F. Outcome results of the Fosinopril versus Amlodipine Cardiovascular Events randomised Trial (FACET) in patients with hypertension and non-insulin dependent diabetes mellitus. Diabetes Care 1998; 21: 597–603.

    Article  PubMed  CAS  Google Scholar 

  72. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. New England Journal of Medicine 1999; 340: 677–684.

    Article  PubMed  CAS  Google Scholar 

  73. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755–1762.

    Article  PubMed  CAS  Google Scholar 

  74. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, de Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–616.

    Article  PubMed  CAS  Google Scholar 

  75. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes — UKPDS 38. British Medical Journal 1998; 317: 703–713.

    Article  Google Scholar 

  76. UK Prospective Diabetes Study (UKPDS) Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes — UKPDS 39. British Medical Journal 1998; 317: 713–720.

    Article  Google Scholar 

  77. Passa P, Chatellier G. The Diab-HYCAR study. Diabetologia 1996; 39: 1662–1667.

    Article  PubMed  CAS  Google Scholar 

  78. Gerstein HC, Bosch J, Pogue J, Taylor DW, Zinman B, Yusuf S. Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes Prevention Evaluation. Diabetes Care 1996; 19: 1225–1228.

    Article  PubMed  CAS  Google Scholar 

  79. Davis BR, Cutler JA, Gordon DJ, Furberg CD, Wright JT, Cushman WC, Grimm RH, Larosa J, Whelton PK, Perry HM, Alderman MH, Ford CE, Oparil S, Francis C, Proschan M, Pressel S, Black HR, Hawkins CM. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). American Journal of Hypertension 1996; 9: 342–360.

    Article  PubMed  CAS  Google Scholar 

  80. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of Ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet, 2000; 355: 253–259.

    Article  Google Scholar 

  81. Remuzzi G, Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules? Kidney Int 1990; 38: 384–394.

    Article  PubMed  CAS  Google Scholar 

  82. Rossing P, Hommel E, Smidt UM, Parving HH. Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients. Diabetes 1993; 42: 715–719.

    Article  PubMed  CAS  Google Scholar 

  83. Lebovitz HE, Wiegmann TB, Cnaan A, Shahinfar S, Sica DA, Broadstone V, Schwartz SL, Mengel MC, Segal R, Versaggi JA, et al. Renal protective effects of enalapril in hypertensive NIDDM: role of baseline albuminuria. Kidney Int Suppl 1994; 45: S 150–155.

    CAS  Google Scholar 

  84. Fioretto P, Stehouwer CD, Mauer M, Chiesura-Corona M, Brocco E, Carraro A, Bortoloso E, van Hinsbergh VW, Crepaldi G, Nosadini R. Heterogeneous nature of microalbuminuria in NIDDM: studies of endothelial function and renal structure. Diabetologia 1998; 41: 233–236.

    Article  PubMed  CAS  Google Scholar 

  85. Cordonnier DJ, Pinel N, Barro C, Maynard M, Zaoui P, Halimi S, de Ligny BH, Reznic Y, Simon D, Bilous RW. Expansion of cortical interstitium is limited by converting enzyme inhibition in type 2 diabetic patients with glomerulosclerosis. The Diabiopsies Group. J Am Soc Nephrol 1999; 10: 1253–1263.

    PubMed  CAS  Google Scholar 

  86. Gilbert RE, Tsalamandris C, Bach L, Panagiotopoulos S, O’Brien RC, Allen TJ, Goodall I, Young V, Seeman E, Murray RML, Cooper ME, Jerums G. Glycemic control and the rate of progression of early diabetic kidney disease: a nine year longitudinal study. Kidney Int 1993; 44: 855–859.

    Article  PubMed  CAS  Google Scholar 

  87. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995; 28: 103–117.

    Article  PubMed  CAS  Google Scholar 

  88. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977–986.

    Article  Google Scholar 

  89. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837–853.

    Article  Google Scholar 

  90. Ravid M, Brosh D, Ravid-Safran D, Levy Z, Rachmani R. Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia. Arch Intern Med 1998; 158: 998–1004.

    Article  PubMed  CAS  Google Scholar 

  91. Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999; 353: 617–622.

    Article  PubMed  CAS  Google Scholar 

References

  1. Hricik DE, Browning PJ, Kopelman R, Goomo WE, Madias NE, Dzau VJ. Captopril induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney. N Engl J Med 1983; 308: 373–376.

    Article  PubMed  CAS  Google Scholar 

  2. Sawicki PT, Kaiser S, Heinernann L, Frenzel H, Berger M. Prevalence of renal artery stenosis in diabetes mellitus—an autopsy study. J Intern Med 1991; 229: 489–492.

    Article  PubMed  CAS  Google Scholar 

  3. Ritchie CM, MeGrath E, Hadden DR, Weaver JA, Kennedy L. Renal artery stenosis in hypertensive diabetic patients. Diab Med 1988; 5: 265–267.

    Article  CAS  Google Scholar 

  4. Jean WJ, al Bitar I, Zwicke DL, Port SC, Schmidt DH, Bajwa TK. High incidence of renal artery stenosis in patients with coronary artery disease. Cathet Cardiovasc Diagn 1994; 32: 8–10.

    Article  PubMed  CAS  Google Scholar 

  5. Isaksson H, Danielsson Nt Rosenhamer G, Konarski Svensson JC, Ostergren J. Characteristics of patients resistant to antihypertensive drug therapy. J Intern Med 1991; 229: 421–426.

    Article  PubMed  CAS  Google Scholar 

  6. Robinson ACJ, Kong C, Henzen C, Pacy P, Chong P, Gedroyc W, Elkeles RS, Robison S. Magnetic resonance angiography and renal artery stenosis in hypertensive patients with type 2 diabetes (Abstract). Diabetologia, 1996; 39 suppl. 1:A36

    Google Scholar 

  7. Courreges JP, Bacha J, Maraoui M, Taurines H, Paris F, Aboud E. Renal artery stenosis prevalence in non-insulin dependent diabetes (NIDDM) and hypertension. (Abstract) Diabetologia, 1995; suppl. 1: A269.

    Google Scholar 

  8. Johnston CI. Angiotensin receptor antagonists: focus on losartan. Lancet, 1995; 346: 1403–1407.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of Melbourne, Austin & Repatriation Medical Centre (Repatriation Campus) West Heidelberg Australia and Leicester Royal Infirmary NHS Trust, Leicester, UK

    Mark E. Cooper, Paul G. McNally & Geoffrey Boner

Authors
  1. Mark E. Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul G. McNally
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Geoffrey Boner
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medical Department M (Diabetes & Endocrinology), Aarhus Kommunehospital Aarhus University Hospital, Aarhus C, Denmark

    Carl Erik Mogensen

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Springer Science+Business Media New York

About this chapter

Cite this chapter

Cooper, M.E., McNally, P.G., Boner, G. (2000). Antihypertensive Treatment in NIDDM, with Special Reference to Abnormal Albuminuria. In: Mogensen, C.E. (eds) The Kidney and Hypertension in Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-4499-9_35

Download citation

  • DOI: https://doi.org/10.1007/978-1-4615-4499-9_35

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-7028-4

  • Online ISBN: 978-1-4615-4499-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation